Classification and therapeutic approaches in autoimmune hemolytic anemia: an update

References

• Petz LD, Garraty G. Immune Haemolytic Anemias (2nd Edition). Churchill Livingstone, PA, USA (2004).
   Google Scholar
• Gerhrs BS, Friedberg RC. Autoimmune hemolytic anemia. Am. J. Hematol.69, 258–271 (2002).
   PubMedGoogle Scholar
• Sokol RJ, Booker DJ, Stamps R. The pathology of autoimmune haemolytic anemia. J. Clin. Pathol.45, 1047–1052 (1992).
   PubMed Web of Science ®Google Scholar
• Aladjidi N, Leverger G, Leblanc T et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica96(5), 655–663 (2011).
   PubMed Web of Science ®Google Scholar
• Genty I, Michel M, Hermine O et al. [Characteristics of autoimmune hemolytic anemia in adults: retrospective analysis of 83 cases]. Rev. Med. Int.23, 901–909 (2002).
   PubMed Web of Science ®Google Scholar
• Packman CH. Hemolytic anemia due to warm autoantibodies. Blood Rev.22, 17–31 (2008).
   PubMed Web of Science ®Google Scholar
• Michel M, Chanet V, Dechartres A et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood114(15), 3167–3172 (2009).
   PubMed Web of Science ®Google Scholar
• Barros MMO, Blajchman MA, Bordin JO. Warm autoimmune haemolytic anemia: recent progress in understanding the immunobiology and treatment. Transfus. Med. Rev.24, 195–210 (2010).
   PubMed Web of Science ®Google Scholar
• Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood105, 3746–3748 (2005).
   PubMed Web of Science ®Google Scholar
• Semple JW, Freedman J. Autoimmune pathogenesis and autoimmune hemolytic anemia. Sem. Hematol.42, 122–130 (2005).
   PubMed Web of Science ®Google Scholar
• Michel M. [Characteristics of warm autoimmune hemolytic anemia and Evans syndrome in adults]. Presse Med.37(9), 1309–1318 (2008).
   PubMed Web of Science ®Google Scholar
• Petz LD. Cold antibody autoimmune haemolytic anemias. Blood Rev.22, 1–15 (2008).
   PubMed Web of Science ®Google Scholar
• Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Sem. Hematol.42, 137–144 (2005).
   PubMed Web of Science ®Google Scholar
• Garbe E, Andersohn F, Bronder E et al. Drug induced immune haemolytic anaemia in the Berlin Case–Control Surveillance Study. Br. J. Haematol.154, 644–653 (2011).
   PubMed Web of Science ®Google Scholar
• Tsuruta R, Kawamura Y, Inoue T, Kasaoka S, Sadamitsu D, Maekawa T. Corticosteroid therapy for haemolytic anemia and respiratory failure due to Mycoplasma pneumoniae pneumonia. Intern. Med.41, 229–232 (2002).
   PubMedGoogle Scholar
• Mason HM, Ardnt PA. A 13 year-old girl with cold agglutinin syndrome caused by anti-i. J. Pediatr. Hematol. Oncol.30, 543–545 (2008).
   PubMedGoogle Scholar
• Berentsen S, Ulvestad E, Langholm R et al. Primary cold agglutinin disease: a population based clinical study of 86 patients. Haematologica91, 460–466 (2006).
   PubMed Web of Science ®Google Scholar
• Lechner K, Jäger U. How I treat autoimmune hemolytic anemias in adults. Blood116(11), 1831–1838 (2010).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Gjertsen BT et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood103, 2925–2928 (2004).
   PubMed Web of Science ®Google Scholar
• Schöllkopf C, Kjeldsen L, Weiss Bjerrum O et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk. Lymphoma47, 253–260 (2006).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Randen U, Vågan AM et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood116(17), 3180–3184 (2010).
   PubMed Web of Science ®Google Scholar
• Crowther M, Chan YT, Garbett IK, Lim W, Vickers MA, Crowther MA. Evidence-based focused review of the treatment of idiopathic warm immune hemolytic anemia in adults. Blood doi:10.1182/blood-2011-05-347708 (2011) (Epub ahead of print).
   Google Scholar
• Berentsen S, Tjønnfjord GE, Shammas FV et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur. J. Haematol.65(1), 88–90 (2000).
   PubMed Web of Science ®Google Scholar
• Petz LD. Cold antibody autoimmune hemolytic anemia. Blood Rev.22, 1–5 (2008).
   PubMed Web of Science ®Google Scholar
• Hippe E, Jensen KB, Olesen H et al. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood35, 68–72 (1979).
   Google Scholar
• McLeod BC. Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias. Curr. Opin. Hematol.14, 647–654 (2007).
   PubMed Web of Science ®Google Scholar
• Röth A, Hüttmann A, Rother RP et al. Long term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood113, 3885 (2009).
   PubMed Web of Science ®Google Scholar
• Salama A, Berghöfer H, Mueller-Eckhardt C. Red blood cell transfusion in warm-type autoimmune haemolytic anaemia. Lancet340, 1515–1517 (1992).
   PubMed Web of Science ®Google Scholar
• Shirey RS, Boyd JS, Parwani AV et al. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion42, 1435–1441(2002).
   PubMed Web of Science ®Google Scholar
• Branch DR, Petz LD. Detecting alloantibodies in patients with autoantibodies. Transfusion39, 6–10 (1999).
   PubMed Web of Science ®Google Scholar
• Wallhermfechtel MA, Pohl BA, Chaplin H. Alloimmunization in patients with warm autoantibodies. A retrospective study employing three donor alloabsorptions to aid in antibody detection. Transfusion24, 482–485 (1984).
   PubMedGoogle Scholar
• Ruivard M, Tournilhac O, Montel S et al. Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: a retrospective case–control study. J. Clin. Apher.21, 202–206 (2006).
   PubMed Web of Science ®Google Scholar
• Flores G, Cunningham-Rundles C, Newland AC, Bussel JB. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia; results in 73 patients. Am. J. Hematol.44, 237–242 (1993).
   PubMed Web of Science ®Google Scholar
• Pignon JM, Poirson E, Rochant H. Danazol in autoimmune haemolytic anemia. Br. J. Haematol.83, 343–345 (1993).
   PubMed Web of Science ®Google Scholar
• Ahn YS. Efficacy of danazol in hematologic disorders. Acta Haematol.84, 122–129 (1990).
   PubMed Web of Science ®Google Scholar
• Coon WW. Splenectomy in the treatment of hemolytic anemia. Arch. Surg.120, 625–628 (1985).
   PubMed Web of Science ®Google Scholar
• Alpeck G, McAneny D, Weintraub L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated diseases. Am. J. Hematol.61, 98–102 (1999).
   PubMedGoogle Scholar
• Vecchio R, Cacciola E, Cacciola RR, Marchese S, Intagliata E. Portal vein thrombosis after laparoscopic and open splenectomy. J. Laparoendosc. Adv. Surg. Tech. A21(1), 71–75 (2011).
   PubMedGoogle Scholar
• Krauth MT, Lechner K, Neugebauer EA, Pabinger I. The postoperative splenic/portal vein thrombosis after splenectomy and its prevention – an unresolved issue. Haematologica93(8), 1227–1232 (2008).
   PubMed Web of Science ®Google Scholar
• Hendrick AM. Autoimmune haemolytic anemia – a high risk for thromboembolism? Hematology8, 53–56 (2003).
   PubMedGoogle Scholar
• Bonderman D, Skoro-Sajer N, Jakowitsch J et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation115(16), 2153–2158 (2007).
   PubMed Web of Science ®Google Scholar
• Jaïs X, Ioos V, Jardim C et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax60(12), 1031–1034 (2005).
   PubMed Web of Science ®Google Scholar
• Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br. J. Haematol.141, 149–169 (2008).
   PubMed Web of Science ®Google Scholar
• Quartier P, Brethon B, Philippet P et al. Treatment of childhood autimmune haemolytic anemia with rituximab. Lancet358, 1511–1513 (2011).
   Google Scholar
• Zecca M, Nobili B, Ramenghi U et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood101, 3857–3861 (2003).
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia and Evans syndrome. Mayo Clin. Proc.78, 1340–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Narat S, Gandla J, Hoffbrand AV et al. Rituximab in the treatment of refractory autoimmune cytopenias. Haematologica90, 1273–1274 (2003).
   Google Scholar
• D’Arena G, Califano C, Annunziata M et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur. J. Hematol.79, 53–58 (2007).
   PubMed Web of Science ®Google Scholar
• Bussone G, Ribeiro E, Dechartres A et al. Efficacy and safety of rituximab in adults’ warm antibody autoimmune hemolytic anemia: retrospective analysis of 27 cases. Am. J. Hematol.84, 153–157 (2009).
   PubMedGoogle Scholar
• Moyo VM, Smith D, Brodsky I et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood100, 704–706 (2002).
   PubMed Web of Science ®Google Scholar
• Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory autoimmune haemolytic anemia and autoimmune thrombocytopenic purpura. Br. J. Haematol.117, 712–715 (2002).
   PubMed Web of Science ®Google Scholar
• Zimmer-Molsberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anemia. Lancet350, 1003–1004 (1997).
   PubMed Web of Science ®Google Scholar
• Howard J, Hoffbrand AV, Prentice HG et al. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br. J. Haematol.117, 712–715 (2002).
   PubMed Web of Science ®Google Scholar
• Hershko C, Sonnenblick M, Ashkenazi J. Control of steroid-resistant autoimmune haemolytic anemia by cyclosporine. Br. J. Haematol.76, 436–437 (1990).
   PubMed Web of Science ®Google Scholar
• Emilia G, Messora C, Longo G, Bertesi M. Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br. J. Haematol.93, 341–347 (1996).
   PubMed Web of Science ®Google Scholar
• Passweg JR, Rabusin M, Musso M et al. Haematopoetic stem cell transplantation for refractory autoimmune cytopenia. Br. J. Haematol.125, 749–755 (2004).
   PubMed Web of Science ®Google Scholar
• Moyo VM, Smith D, Brodsky I et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood100(2), 704–706 (2002).
   PubMed Web of Science ®Google Scholar
• Willis F, Marsh JCW, Bevan DH et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br. J. Hematol.114, 891–898 (2011).
   Google Scholar
• Kokori SI, Ioannidis JP, Voulgarellis M et al. Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. Am. J. Med.108, 198–204 (2000).
   PubMed Web of Science ®Google Scholar
• Pullakart V, Ngo M, Iqbal S et al. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anemia at increased risk for venous thromboembolism. Br. J. Haematol.118, 1166–1169 (2002).
   PubMedGoogle Scholar
• Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum.62(8), 2458–2466 (2010).
   PubMed Web of Science ®Google Scholar
• Patel S, Kramer N, Rosenstein ED. Evolving connective tissue disease influenced by splenectomy: beneath the sword of Dameshek. J. Clin. Rheumatol.16(6), 280–283 (2010).
   PubMedGoogle Scholar
• You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann. Surg.240(2), 286–292 (2004).
   PubMedGoogle Scholar
• Moreno C, Hodgson K, Ferrer G et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood116(23), 4771–4776 (2010).
   PubMed Web of Science ®Google Scholar
• Zent CS, Ding W, Schwager SM et al. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br. J. Haematol.141(5), 615–621 (2008).
   PubMed Web of Science ®Google Scholar
• Dearden C, Wade R, Else M et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood111(4), 1820–1826 (2008).
   PubMed Web of Science ®Google Scholar
• Zanotti R, Frattini F, Ghia P et al. ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients. Am. J. Hematol.85(7), 494–498 (2010).
   PubMed Web of Science ®Google Scholar
• D’Arena G, Laurenti L, Capalbo S et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am. J. Hematol.81(8), 598–602 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta N, Kavuru S, Patel D et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia16(10), 2092–2095 (2002).
   PubMed Web of Science ®Google Scholar
• Bowen DA, Call TG, Shanafelt TD et al. Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. Leuk. Lymphoma51(4), 620–627 (2010).
   PubMed Web of Science ®Google Scholar
• Rossignol J, Michallet AS, Oberic et al. Rituximab–cyclophosphamide–dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia25(3), 473–478 (2011).
   PubMed Web of Science ®Google Scholar
• Michallet AS, Rossignol J, Cazin B, Ysebaert L. Rituximab–cyclophosphamide–dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leuk. Lymphoma52(7), 1401–1403 (2011).
   PubMed Web of Science ®Google Scholar
• Cortes J, O’Brien S, Loscertales J et al. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer92, 2016–2022 (2001).
   PubMed Web of Science ®Google Scholar
• Hill J, Walsh RM, McHam S, Brody F, Kalaycio M. Laparoscopic splenectomy for autoimmune hemolytic anemia in patients with chronic lymphocytic leukemia: a case series and review of the literature. Am. J. Hematol.75(3), 134–138 (2004).
   PubMed Web of Science ®Google Scholar
• Osterborg A, Karlsson C, Lundin J. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep.4(1), 47–53 (2009).
   PubMedGoogle Scholar
• Karlsson C, Hansson L, Celsing F, Lundin J. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia21(3), 511–514 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez H, Leblond V, Azar N et al. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine. Hematol. Cell Ther.40(3), 113–118 (1998).
   PubMedGoogle Scholar
• Gamberale R, Fernández-Calotti P, Sánchez-Avalos R et al. The effect of fludarabine on interferon-gamma production by lymphoid cells from healthy donors and patients with B-cell chronic lymphocytic leukemia. Haematologica91(4), 574–576 (2006).
   PubMedGoogle Scholar
• Borthakur G, O’Brien S, Wierda WG et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab – incidence and predictors. Br. J. Haematol.136(6), 800–805 (2007).
   PubMed Web of Science ®Google Scholar
• Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program2008, 450–456 (2008).
   Google Scholar
• Sicherer SH, Winkelstein JA. Primary immunodeficiency diseases in adults. JAMA279, 58–61 (1998).
   PubMedGoogle Scholar
• Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol.92, 34–48 (1999).
   PubMed Web of Science ®Google Scholar
• Michel M, Chanet V, Galicier L et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine83, 254–263 (2004).
   PubMed Web of Science ®Google Scholar
• Seve P, Bourdillon L, Sarrot-Reynauld F et al. Autoimmune hemolytic anemia and common variable immunodeficiency: a case–control study of 18 patients. Medicine87, 177–184 (2008).
   PubMed Web of Science ®Google Scholar
• Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J. Autoimmun.25, 57–62 (2005).
   PubMed Web of Science ®Google Scholar
• Gobert D, Bussel JB, Cunningham-Rundles C et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicenter study on 33 patients. Br. J. Haematol. doi:10.1111/j.1365-2141.2011.08880.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Nugent D, McMillan R, Nichol JI et al. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br. J. Haematol.146, 585–596 (2009).
   PubMed Web of Science ®Google Scholar